Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

AI speeds up measurement process

How to inspect coatings ten times faster with a light microscope? The medical technology group Smith+Nephew has been using ZEISS Axio Imager.Z2m since summer 2022.

Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”

What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...

Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt ...

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Reliably gripping and turning small parts

The extremely compact rotary gripper module EHMD is the ideal choice in many life science applications where small objects need to be gripped and turned in conf...

QPS Netherlands B.V

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Ossiform: Quality control of 3D printed bone implants

Ossiform chose the GOM Scan 1.

RegSmart Life Science AB

LINK Medical Research

Öppen frågestund: Regulatory Opportunities for Rare Diseases/Orphan Products in US and EU

Anmäl dig till vår nästa session av Office Hours den 28 februari klockan 15:00 (svensk tid), en öppen frågestund om utveckling av särläkemedel (orphan drugs).

Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”

”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain mar...

Save time and money !

Festo Digital engineering tools helps you to calculate the most cost and efficient solution for your application for free

WuXi AppTec, UK Ltd

FDA-beslut: AZ:s nasala influensavaccin får tas av patienten själv

Astra Zenecas nasala influensavaccin Flumist har godkänts för självadministrering i USA. Det är därmed det första influensavaccinet i USA som inte behöver ges av en vårdgivare.

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas

Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...